Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study
Authors
Yeong Ok Baik (ORCID: https://orcid.org/0000-0001-9935-9264)
Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study
Yeong Ok Baik, Patricia Njuguna, Youngran Park, Djibril Wade et al.
Journal
The Lancet Global Health
Topics
Virus-based gene therapy research
article
Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study
Yeong Ok Baik, Patricia Njuguna, Youngran Park, Djibril Wade, Laina D. Mercer, Frederick J. Cassels, Birane Cissé, B Ndiaye, Winnie Keter, Ndeye Sakha Bob, Michael Raine, Moussa Dia, Gamou Fall, Rahsan Erdem, Sookyung Kim, Chankyu Lee, Lucy Koech, Emily Locke, Howard Her, John J Aponte, Niles Eaton, Faith Riziki, Siry Diye
article en
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Global HealthVol. 13(12)
Institutions
Program for Appropriate Technology in Health (US), Institute of Health Research, Epidemiological Surveillance and Training (SN), Institut Pasteur de Dakar (SN), EuBiologics (South Korea) (KR)